MedPlus Health Services Ltd. (MEDPLUS) AI Stock Analysis

• Market Cap: ₹101.09B
• Dividend Yield: N/A
• Average Volume (3M): 20.61K
• Price to Earnings (P/E): 56.0
• Beta (1Y): 0.37
• Revenue Growth: 6.18%
• EPS Growth: 134.11%
• Country: IN
• Employees: 23,415
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 3.50
• Shares Outstanding: 119,822,580
• 10 Day Avg. Volume: 2,376
• 30 Day Avg. Volume: 20,608
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹891.00
• Price Target Upside: 5.98% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: ₹891.00 ▲(5.98% Upside)

MedPlus Health Services demonstrates strong financial performance with robust cash flow and revenue growth, but faces challenges with cost management and leverage. Technical indicators show neutral to bearish signals, and the stock's high P/E ratio suggests overvaluation. The absence of earnings call and corporate events data limits further insights.

MedPlus Health Services Ltd. Business Overview & Revenue Model

Company Description

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It offers pharmaceutical and wellness products, including medicines, vitamins, medical devices, and test kits; fast-moving consumer goods, such as toiletries, baby care products, soaps, detergents, and sanitizers. The company also provides wholesale cash and carry, and pathological laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. As of March 31, 2021, it operated through 1,659 stores located in the states of Karnataka, Tamil Nadu, Telangana, and Andhra Pradesh, as well as through its online store. The company was incorporated in 2006 and is based in Hyderabad, India.

How the Company Makes Money

MedPlus Health Services Ltd. generates revenue primarily through its extensive network of retail pharmacies across India. The company earns money by selling pharmaceutical products, which include both branded and generic medicines. Additionally, MedPlus offers a variety of health and wellness products, such as nutritional supplements and personal care items, contributing to its revenue streams. The company also provides diagnostic services, adding another layer to its earnings model. MedPlus leverages its supply chain and distribution capabilities to maintain a consistent product availability, which enhances customer satisfaction and drives sales. Strategic partnerships with pharmaceutical manufacturers and healthcare providers further bolster its revenue by ensuring a diverse product range and competitive pricing.

MedPlus Health Services Ltd. Financial Statement Overview

Summary

MedPlus Health Services Ltd. shows a positive growth trajectory with improved profitability and strong cash flow generation. While revenue and net income growth are commendable, the company faces challenges in maintaining gross profit margins and managing increasing debt levels.

Income Statement

MedPlus Health Services has shown consistent revenue growth with an increase from 28,512.52 million to 61,360.53 million over the years. However, the gross profit margin has seen a significant drop from 2024 to 2025, indicating pressure on cost management. The net profit margin improved to 2.45% in 2025, showing better profitability control. The EBIT and EBITDA margins are stable, reflecting effective operational management.

Balance Sheet

The debt-to-equity ratio is 0.64, indicating a moderate level of leverage. Return on equity has improved, showing enhanced profitability with a focus on equity efficiency. The equity ratio stands at 51.80%, suggesting a balanced capital structure with a strong equity base. However, the increase in total debt over the years signals potential risk if not managed carefully.

Cash Flow

The company has demonstrated strong free cash flow growth, with substantial improvement from negative to 4,949.57 million, indicating robust cash generation capabilities. The operating cash flow to net income ratio is favorable, reflecting efficient cash management. However, fluctuations in investing and financing cash flows suggest active capital management and investment strategies.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	61.17B	61.36B	56.25B	37.55B	45.58B	30.51B
Gross Profit	9.89B	5.20B	12.14B	7.73B	10.00B	6.26B
EBITDA	4.91B	5.36B	3.94B	3.04B	3.12B	2.38B
Net Income	1.32B	1.50B	654.73M	958.02M	497.63M	638.58M
Balance Sheet
Total Assets	0.00	33.60B	30.05B	25.94B	27.97B	15.66B
Cash, Cash Equivalents and Short-Term Investments	2.68B	3.67B	1.65B	6.58B	2.96B	1.49B
Total Debt	0.00	11.20B	10.10B	8.15B	9.00B	5.90B
Total Liabilities	-16.36B	16.20B	14.27B	11.77B	13.06B	8.35B
Stockholders Equity	16.36B	17.41B	15.78B	14.18B	14.91B	7.31B
Cash Flow
Free Cash Flow	0.00	4.95B	593.38M	521.68M	-785.95M	-513.67M
Operating Cash Flow	0.00	5.54B	1.44B	1.70B	904.10M	28.91M
Investing Cash Flow	0.00	-3.32B	-827.99M	-7.03B	4.29B	-345.49M
Financing Cash Flow	0.00	-2.28B	-1.98B	4.40B	-1.70B	-56.26M

MedPlus Health Services Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 840.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDPLUS, the sentiment is Negative. The current price of 840.7 is above the 20-day moving average (MA) of 836.46, below the 50-day MA of 859.13, and above the 200-day MA of 823.22, indicating a neutral trend. The MACD of -4.07 indicates Negative momentum. The RSI at 46.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDPLUS.

MedPlus Health Services Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
METROPOLIS	72 Outperform	110.56B	72.28	10.89%	―	12.86%	10.42%
LALPATHLAB	70 Outperform	291.40B	53.36	22.42%	0.69%	10.57%	34.11%
VIJAYA	68 Neutral	108.56B	71.48	17.98%	0.19%	22.34%	20.71%
MEDPLUS	62 Neutral	₹101.09B	56.04		―	6.18%	134.11%
HCG	61 Neutral	90.46B	243.93	4.81%	―	16.85%	-29.57%
INDOCO	46 Neutral	27.76B	-24.74	-7.22%	0.07%	-8.28%	-246.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

MedPlus Health Services Ltd. Corporate Events

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Karnataka. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 1.06 lacs, impacting the company’s financial operations in the region.

MedPlus Health Services Announces Dispatch of AGM Notice

MedPlus Health Services Ltd. has announced the completion of dispatching the notice for its 19th Annual General Meeting, which has been published in the ‘Financial Express’ and ‘Nava Telangana’ newspapers. This announcement is part of the company’s compliance with SEBI regulations and is accessible on their website and the websites of BSE and NSE, indicating their commitment to transparency and regulatory adherence.

MedPlus Health Services Files BRSR for FY 2024-25

MedPlus Health Services Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25, in compliance with SEBI regulations. This report, which is part of the company’s annual report, provides insights into MedPlus’s environmental, social, and governance (ESG) performance, highlighting its commitment to transparency and accountability in sustainable development.

MedPlus Health Services Releases Q1 2025 Financial Results

MedPlus Health Services Ltd. announced the approval of its un-audited standalone and consolidated financial results for the quarter ended June 30, 2025. These results have been published in prominent newspapers and are available on the company’s website as well as on the BSE and NSE websites. This announcement reflects MedPlus’s commitment to transparency and compliance with SEBI regulations, potentially impacting investor confidence and market positioning.

MedPlus Health Services Announces Earnings Call for Q2 2025

MedPlus Health Services Ltd. has announced an earnings call scheduled for August 4, 2025, to discuss its unaudited financial results for the quarter ended June 30, 2025. This call is part of the company’s compliance with SEBI regulations and is aimed at engaging with analysts and institutional investors. The announcement underscores MedPlus’s commitment to transparency and maintaining strong communication with its stakeholders.

MedPlus Subsidiary Faces Temporary Drug License Suspension in Karnataka

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license at one of its stores in Karnataka. This suspension, issued by the Drugs Control Administration in Bangalore, will last for three days and is expected to result in a potential revenue loss of approximately Rs 0.37 lacs. The suspension is due to violations under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. This development could impact the company’s operations and market positioning, highlighting the importance of regulatory compliance for stakeholders.

MedPlus Health Services Secures SEBI Compliance Certificate

MedPlus Health Services Ltd. has announced the receipt of a compliance certificate from KFIN Technologies Limited, its Registrar and Transfer Agents, in accordance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate, which pertains to the dematerialization and rematerialization of securities for the quarter ending June 30, 2025, has been shared with all stock exchanges where the company is listed, ensuring transparency and regulatory adherence.

MedPlus Health Services Secures Stay Orders Against Suspension

MedPlus Health Services Ltd. announced that it has received two Stay Orders against a suspension from appropriate authorities in Pune, Maharashtra. This development is significant as it may impact the company’s operations and its positioning in the healthcare market, potentially affecting stakeholders.